Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 388

1.

Residual Viremia in Treated HIV+ Individuals.

Conway JM, Perelson AS.

PLoS Comput Biol. 2016 Jan 6;12(1):e1004677. doi: 10.1371/journal.pcbi.1004677. eCollection 2016 Jan.

2.

SPMM: estimating infection duration of multivariant HIV-1 infections.

Love TM, Park SY, Giorgi EE, Mack WJ, Perelson AS, Lee HY.

Bioinformatics. 2015 Dec 31. pii: btv749. [Epub ahead of print]

PMID:
26722117
3.

Recombination Enhances HIV-1 Envelope Diversity by Facilitating the Survival of Latent Genomic Fragments in the Plasma Virus Population.

Immonen TT, Conway JM, Romero-Severson EO, Perelson AS, Leitner T.

PLoS Comput Biol. 2015 Dec 22;11(12):e1004625. doi: 10.1371/journal.pcbi.1004625. eCollection 2015 Dec.

4.

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM; ACTG A5249s protocol team.

AIDS. 2015 Nov 28;29(18):2419-26. doi: 10.1097/QAD.0000000000000843.

PMID:
26558541
5.

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

Canini L, Guedj J, Chatterjee A, Lemenuel-Diot A, Smith PF, Perelson AS.

Antivir Ther. 2015 Nov 10. doi: 10.3851/IMP3006. [Epub ahead of print]

PMID:
26555159
6.

Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.

Ke R, Lewin SR, Elliott JH, Perelson AS.

PLoS Pathog. 2015 Oct 23;11(10):e1005237. doi: 10.1371/journal.ppat.1005237. eCollection 2015 Oct.

7.

Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification.

Li H, Stoddard MB, Wang S, Giorgi EE, Blair LM, Learn GH, Hahn BH, Alter HJ, Busch MP, Fierer DS, Ribeiro RM, Perelson AS, Bhattacharya T, Shaw GM.

J Virol. 2015 Oct 14;90(1):152-66. doi: 10.1128/JVI.02156-15.

8.

Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.

Luo S, Perelson AS.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11654-9. doi: 10.1073/pnas.1505207112. Epub 2015 Aug 31.

PMID:
26324897
9.

The challenges of modelling antibody repertoire dynamics in HIV infection.

Luo S, Perelson AS.

Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676). pii: 20140247. doi: 10.1098/rstb.2014.0247. Review.

PMID:
26194760
10.

Modelling hepatitis C therapy--predicting effects of treatment.

Perelson AS, Guedj J.

Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):437-45. doi: 10.1038/nrgastro.2015.97. Epub 2015 Jun 30. Review.

PMID:
26122475
11.

Post-treatment control of HIV infection.

Conway JM, Perelson AS.

Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5467-72. doi: 10.1073/pnas.1419162112. Epub 2015 Apr 13.

12.

Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach.

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H.

J Virol. 2015 Jul;89(13):6551-61. doi: 10.1128/JVI.00016-15. Epub 2015 Apr 1.

13.

Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo.

Smith NM, Mlcochova P, Watters SA, Aasa-Chapman MM, Rabin N, Moore S, Edwards SG, Garson JA, Grant PR, Ferns RB, Kashuba A, Mayor NP, Schellekens J, Marsh SG, McMichael AJ, Perelson AS, Pillay D, Goonetilleke N, Gupta RK.

Clin Infect Dis. 2015 Jul 1;61(1):120-8. doi: 10.1093/cid/civ219. Epub 2015 Mar 16.

14.

Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.

Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E.

PLoS Pathog. 2015 Jan 8;11(1):e1004565. doi: 10.1371/journal.ppat.1004565. eCollection 2015 Jan.

15.

Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation.

Liu D, Zuo T, Hora B, Song H, Kong W, Yu X, Goonetilleke N, Bhattacharya T, Perelson AS, Haynes BF, McMichael AJ, Gao F.

Retrovirology. 2014 Nov 19;11:101. doi: 10.1186/s12977-014-0101-0.

16.

Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.

Graw F, Balagopal A, Kandathil AJ, Ray SC, Thomas DL, Ribeiro RM, Perelson AS.

PLoS Comput Biol. 2014 Nov 13;10(11):e1003934. doi: 10.1371/journal.pcbi.1003934. eCollection 2014 Nov.

17.

Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells.

Althaus CL, Joos B, Perelson AS, G√ľnthard HF.

PLoS Comput Biol. 2014 Oct 23;10(10):e1003871. doi: 10.1371/journal.pcbi.1003871. eCollection 2014 Oct.

18.

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

Canini L, Chatterjee A, Guedj J, Lemenuel-Diot A, Brennan B, Smith PF, Perelson AS.

Antivir Ther. 2015;20(5):469-77. doi: 10.3851/IMP2879. Epub 2014 Oct 16.

19.

Modeling the dynamics and migratory pathways of virus-specific antibody-secreting cell populations in primary influenza infection.

Miao H, Sangster MY, Livingstone AM, Hilchey SP, Zhang L, Topham DJ, Mosmann TR, Holden-Wiltse J, Perelson AS, Wu H, Zand MS.

PLoS One. 2014 Aug 29;9(8):e104781. doi: 10.1371/journal.pone.0104781. eCollection 2014.

20.

A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.

Conway JM, Perelson AS.

PLoS Comput Biol. 2014 Aug 7;10(8):e1003769. doi: 10.1371/journal.pcbi.1003769. eCollection 2014 Aug.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk